{"filings":[{"id":2447519,"accession_number":"0001193805-26-001130","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-08-25T10:00:33+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arcturus to present ARCT-810 OTC deficiency data at SSIEM 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster on ARCT-810 mRNA therapy for ornithine transcarbamylase deficiency at SSIEM 2026 in Helsinki on Aug 25, 2026","Data covers dietary intake and biochemical outcomes in adolescents and adults","Additional data and regulatory plan expected later this quarter","Presentation furnished as Exhibit 99.1 to Form 8-K"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2105797,"accession_number":"0001193805-26-001039","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-08-06T20:06:01+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q2 net loss $23.8M; regains KOSTAIVE rights; ARCT-032 Phase 3 decision Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.8M ($0.84/share) vs $9.2M ($0.34/share) in Q2 2025; revenue fell to $3.0M from $28.3M due to CSL Seqirus termination.","Regained global rights to KOSTAIVE and infectious disease portfolio from CSL Seqirus; received $12M cash and $16M in released liabilities.","ARCT-032 (CF) Phase 2 enrollment on schedule; decision to proceed to Phase 3 expected Q4 2026; Thermo Fisher collaboration for Phase 3.","ARCT-810 (OTC deficiency) Phase 2 enrollment and dosing completed; data and regulatory plan expected Q3 2026.","Cash and cash equivalents $191.5M as of June 30, 2026; cash runway over 2.5 years through year end 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1397036,"accession_number":"0001193805-26-000910","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-07-02T11:05:55+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Arcturus signs $80M collaboration with Thermo Fisher for ARCT-032 CF program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thermo Fisher to provide up to $40M in clinical manufacturing services; Arcturus to spend up to $40M on CRO services via PPD.","Collaboration supports Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.","Upon regulatory approval, Thermo Fisher receives exclusive commercial manufacturing rights for ARCT-032.","Agreement includes technical transfer, clinical trial materials, PPQ batches, and stability studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":890759,"accession_number":"0001193805-26-000770","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-06-05T21:20:32+00:00","items":["5.07"],"status":"ready","headline":"Arcturus Therapeutics shareholders elect all eight director nominees, approve say-on-pay, and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees (Farrell, Payne, Barlow, Holmes, Marquet, Marantz, Markels, Slaoui) elected with over 15M votes each.","Non-binding advisory say-on-pay approved: 15.25M for, 327,647 against, 176,375 abstain.","Ratification of Deloitte as independent auditor for 2026 approved: 21.38M for, 46,823 against, 10,349 abstain.","Quorum of 21.44M shares present out of 28.42M shares entitled to vote.","All proposals passed with no significant opposition; no other business transacted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95298,"accession_number":"0001193805-26-000573","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Arcturus Q1 net loss widens to $27M; appoints Dennis Mulroy as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.0M ($0.95/diluted share), compared to $14.1M loss ($0.52/share) in Q1 2025.","Total operating expenses fell to $31.0M from $46.2M; revenue down $27.3M due to pivot from infectious disease.","Cash and equivalents $213.4M, runway beyond Q2 2028. Cash decreased $19.4M from Dec 2025.","ARCT-032 CF Phase 2 study enrollment initiated; ARCT-810 OTC deficiency gets FDA clarity for pivotal pediatric path.","Dennis Mulroy appointed CFO effective May 1, 2026; base salary $520k, options for 100k shares."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":2061000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108251,"accession_number":"0001193805-26-000214","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus FY2025 net loss narrows to $65.8M; revenue falls 46% to $82M; CF program advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $29.1M ($1.03/shr) vs $30.0M loss prior year; FY net loss $65.8M ($2.40/shr) vs $80.9M.","Revenue Q4 $7.2M, FY $82.0M, down $70.3M YoY due to lower CSL collaboration milestones and supply activity.","Cash $232.8M at Dec 31, 2025; cash runway extended into Q2 2028.","ARCT-032 (CF) third cohort (15 mg, 28 days) safe; 12-week Phase 2 study to start H1 2026.","KOSTAIVE COVID-19 vaccine granted UK MHRA approval in Jan 2026; BARDA pandemic flu vaccine shows durable immune response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124689,"accession_number":"0001193805-25-001734","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Andy Sassine to depart Dec 31, 2025; Controller Joe Roberts named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Andy Sassine and Arcturus mutually agreed to end employment effective Dec 31, 2025; he also resigned from the Board.","Sassine receives severance: 12 months base salary ($572,000), bonus tied to CEO's 2025 bonus, 18 months COBRA, and full acceleration of 134,689 unvested stock options with 24-month exercise period.","Joe Roberts, company Controller since March 2024, appointed interim principal financial and accounting officer; base salary $219,580, 20% target bonus.","Board size reduced from nine to eight members effective immediately upon Sassine's resignation.","Separation Agreement includes non-disparagement, standard release, and revocation period; severance contingent on release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124688,"accession_number":"0001193805-25-001555","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Therapeutics Reports Q3 2025 Net Loss of $13.5M, Progresses ARCT-032 and ARCT-810 Programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue was $17.2M, down $24.5M from prior year; net loss $13.5M ($0.49 per share) vs $6.9M loss in Q3 2024.","ARCT-032 Phase 2 interim data: inhaled 10mg daily over 28 days well tolerated; mucus burden reduced in 4 of 6 Class I CF adults per HRCT scans.","Company plans a 12-week safety and efficacy study of ARCT-032 in up to 20 CF participants starting H1 2026.","FDA changes delayed U.S. BLA filing for KOSTAIVE indefinitely; additional cost reductions planned in Q4 2025 to extend cash runway into 2028.","ARCT-2304 pandemic flu vaccine candidate induced humoral immune response after single dose at all tested levels, supporting further development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":74835000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124687,"accession_number":"0001193805-25-001499","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Arcturus reports ARCT-032 CF interim data showing mucus reduction; KOSTAIVE BLA submission delayed by FDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCT-032 Phase 2 interim: generally safe/tolerated; 4 of 6 Class I CF patients showed mucus plug/volume reduction after 28 days (10 mg).","FDA requested delay of KOSTAIVE BLA submission (Sep 5), then required additional clinical endpoint efficacy study per updated COVID-19 framework.","CSL Seqirus submitted KOSTAIVE MAA to UK MHRA in June 2025; approval expected Q1 2026, but not assured.","Company filed lawsuit Sep 23, 2025 against AbbVie and Capstan Therapeutics for trade secret misappropriation and breach of contract.","12-week safety/efficacy study of ARCT-032 in up to 20 CF participants planned to start first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141381,"accession_number":"0001193805-25-001368","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Meiji Seika Pharma launches two-dose vial of KOSTAIVE (sa-mRNA COVID-19 vaccine) in Japan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New two-dose vial presentation of KOSTAIVE launched in Japan on September 26, 2025.","Vaccine targets SARS-CoV-2 Omicron sublineage JN.1 variant XEC.","Non-clinical studies show neutralizing antibodies against XEC, LP.8.1, XFG, NB.1.8.1 variants.","Manufacturing and marketing approval granted August 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141380,"accession_number":"0001193805-25-001247","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Meiji Seika Pharma receives Japan approval for two-dose vial of KOSTAIVE® COVID-19 vaccine","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Approval granted August 28, 2025 for new two-dose vial presentation of KOSTAIVE® (ARCT-2301) in Japan.","Vaccine targets SARS-CoV-2 Omicron sub lineage JN.1 variant XEC; induces neutralizing antibodies against multiple variants.","Meiji Seika Pharma plans to begin supply of the new presentation starting late September 2025.","Non-clinical data shows neutralizing antibodies against JN.1, XEC, LP.8.1, XFG, and NB.1.8.1 variants.","Distribution in Japan is under a prior agreement between Meiji and CSL Seqirus, partner of Arcturus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141379,"accession_number":"0001193805-25-001175","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q2 revenue $28.3M (-43% YoY); net loss narrows to $9.2M; CF data due Sep","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 43% YoY to $28.3M, driven by lower CSL collaboration activity and KOSTAIVE amortization.","Net loss improved to $9.2M ($0.34 loss per share) from $17.2M loss in Q2 2024.","Operating expenses dropped to $39.9M from $71.0M, mainly on lower KOSTAIVE and flu program costs.","Cash and restricted cash $253.4M, extended runway into 2028.","ARCT-032 CF Phase 2 interim data for 9 participants due Sep 2025; KOSTAIVE UK MAA decision expected Sep 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":57683000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159197,"accession_number":"0001193805-25-000946","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arcturus ARCT-810 Phase 2 interim: glutamine normalized, ureagenesis improved (p=0.026)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combined Phase 2 data show glutamine significantly reduced (p=0.0055); levels normalized after 3 doses in US study.","15N-ureagenesis function (RUF) increased from 29.0% baseline to 43.7% at day 28 post-fifth dose (p=0.026).","Ammonia remained stable and within normal range in both studies; one hyperammonemia event on placebo.","ARCT-810 safe and well tolerated across Phase 1/2 with no serious infusion reactions on optimized 3-hour regimen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159196,"accession_number":"0001193805-25-000820","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcturus shareholders elect all 9 director nominees, approve say-on-pay, ratify Deloitte","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; votes ranged from 18,555,174 (Dr. Holmes) to 19,059,965 (Dr. Slaoui).","Say-on-pay resolution approved: 18,472,131 for, 586,006 against, 64,724 abstain, 2,883,662 broker non-votes.","Ratification of Deloitte & Touche as FY2025 auditor passed: 21,971,168 for, 30,589 against, 4,767 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159195,"accession_number":"0001193805-25-000630","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q1 net loss narrows to $14.1M; cash runway extends into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.1M ($0.52/diluted share) vs $26.8M ($1.00) a year ago; revenue $29.4M down 23% YoY.","Cash, equivalents and restricted cash $273.8M at March 31, 2025; runway extended into 2028 via resource re-allocation.","Received initial EU approval milestone payment from CSL Seqirus for KOSTAIVE COVID-19 vaccine.","ARCT-032 (CF) Phase 2 interim data from first two cohorts expected mid-2025; enrollment to complete by year-end.","ARCT-810 (OTC) Phase 2 interim data expected Q2 2025; FDA Fast Track granted for H5N1 vaccine ARCT-2304."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":29382000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177645,"accession_number":"0001193805-25-000275","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q4 net loss widens to $30M; KOSTAIVE EC approved, Phase 2 data due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $30.0M ($1.11/share) vs $11.7M ($0.44) in Q4 2023; revenue down $8.1M to $22.8M.","Full year 2024 revenue $152.3M (down $14.5M YoY); net loss $80.9M ($3.00/share) vs $29.7M ($1.12).","Cash $293.9M at Dec 31, 2024; runway expected to Q1 2027; CSL reported $28M Arcturus share of KOSTAIVE gross profit.","KOSTAIVE received European Commission approval Feb 2025; US BLA filing anticipated 2025; H5N1 vaccine Phase 1 dosed.","ARCT-032 CF and ARCT-810 OTCD Phase 2 interim data on track for Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194349,"accession_number":"0001193805-24-001318","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q3 net loss narrows to $6.9M; $25M milestone from KOSTAIVE first sale in Japan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $41.7M vs $45.2M YoY, down on lower CSL milestones; net loss $6.9M ($0.26/sh) vs $16.2M ($0.61/sh).","Cash $294.1M; runway extended through Q1 2027. Total $462.1M in upfront and milestone payments from CSL to date.","$25M commercial milestone triggered by first sale of KOSTAIVE in Japan by Meiji Seika Pharma in September.","ARCT-032 CF and ARCT-810 OTC deficiency Phase 2 interim proof-of-concept data expected in first half of 2025.","European CHMP opinion for KOSTAIVE expected December 2024; U.S. BLA filing planned in H1 2025."],"consensus_eps_estimate":-0.8397,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":129544000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210689,"accession_number":"0001193805-24-001023","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arcturus posts updated corporate presentation; details not disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on company website on August 13, 2024.","Presentation content not available in filing; no specific numbers or events reported.","No material changes disclosed in the filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210688,"accession_number":"0001193805-24-000990","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q2 revenue $49.9M, net loss $17.2M; pipeline advances, Kostaive launch on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $49.9M, up $39.4M YoY from $10.5M, driven by CSL collaboration revenue.","Net loss $17.2M ($0.64 per share) improved from $52.6M loss in Q2 2023.","Cash $317.2M; cash runway extends through Q1 2027; $437.1M received from CSL to date.","IND submitted for ARCT-032 Phase 2 cystic fibrosis study; ARCT-810 OTC deficiency interim data expected Q4 2024.","Kostaive on track for Q4 commercial launch in Japan; EMA review ongoing; COVID/flu programs with CSL progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":87871000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229057,"accession_number":"0001193805-24-000842","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcturus Therapeutics appoints Dr. Moncef Slaoui to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Moncef Slaoui, former Chief Scientific Advisor for Operation Warp Speed, appointed independent director effective June 19, 2024.","Slaoui brings vaccine industry expertise; previously served on boards of Moderna, Lonza, Vaxcyte, and held leadership at GSK.","Slaoui will receive standard non-employee director compensation as described in 2024 proxy statement.","No arrangements or family relationships with other directors/officers; no reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229056,"accession_number":"0001193805-24-000806","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Arcturus stockholders approve 2M share increase to equity incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2019 Omnibus Equity Incentive Plan approved: shares increased by 2,000,000 to 10,750,000 total.","All eight director nominees elected (e.g., Peter Farrell, Joseph Payne) to serve until 2025 annual meeting.","Say-on-pay approved with 19,875,930 For, 1,069,592 Against, 58,600 Abstain.","Ratification of Deloitte & Touche LLP as independent auditor for FY 2024 ratified (23,267,449 For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229055,"accession_number":"0001193805-24-000614","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q1 2024 revenue $38M, net loss $26.8M; Kostaive on track for Q3 launch, cash runway through FY2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $38.0M (down 53% YoY); net loss $26.8M ($1.00/share) vs net income $50.8M ($1.87) in Q1 2023.","Cash $345.3M; runway extends at least three years to Q1 FY2027; expects future CSL milestones.","Kostaive commercialization on track: initial 4M doses delivery in Q3; European MAA decision expected Q3.","Phase 3 pivotal study for ARCT-2303 (XBB.1.5) initiated; ARCT-2138 flu Phase 1 topline data expected Q3.","ARCT-810 (OTC) and ARCT-032 (CF) data updates on July 1, 2024; JP Morgan engaged to monetize ARCALIS JV stake."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":38012000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229054,"accession_number":"0001193805-24-000505","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Arcturus Therapeutics dismisses EY as auditor, appoints Deloitte; cites material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Ernst & Young as independent auditor effective April 5, 2024.","EY's 2023 report included an adverse opinion on internal controls over financial reporting, citing material weaknesses in ITGCs and cost review controls.","No disagreements between the company and EY on accounting principles or audit scope during fiscal years 2022 and 2023.","Deloitte & Touche appointed as new independent registered public accounting firm for fiscal year ending December 31, 2024.","Decision followed a competitive process; no prior consultations with Deloitte regarding accounting treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247666,"accession_number":"0001193805-24-000392","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arcturus partner Meiji reports Phase III success for bivalent COVID-19 booster in Japan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bivalent ARCT-2301 (Kostaive) met primary endpoint of non-inferiority vs COMIRNATY bivalent in GMT ratio and SRR difference.","Superiority against Omicron BA.4/5 and Wuhan strain also confirmed in the phase III study in healthy Japanese adults.","No causally-related severe or serious adverse events reported; safety profile supports platform.","Study conducted by Meiji under distribution agreement with CSL Seqirus for Japan market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247663,"accession_number":"0001193805-24-000364","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K/A","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Therapeutics amends FY2023 results: revenue down $3.2M, net loss wider","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration revenue for FY2023 decreased from $160.9M to $157.7M; Q4 2023 from $28.2M to $25.0M.","Updated net loss: FY2023 $29.7M ($1.12 per share); Q4 2023 $11.7M ($0.44 per share).","Adjustments are non-cash: deferred revenue increased $3.2M, offset by reduction in stockholders' equity.","Cash, equivalents, restricted cash and cash runway unchanged.","Annual Report on Form 10-K for FY2023 filed March 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247665,"accession_number":"0001193805-24-000335","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus FY2023 revenue $169.9M, net loss $26.6M; cash runway extended to Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $169.9M (down from $206.0M); net loss $26.6M ($1.00 diluted EPS) vs prior year net income $9.3M ($0.35 EPS).","Q4 2023 revenue $34.0M (down from $160.3M in Q4 2022, which included $200M CSL upfront); Q4 net loss $8.6M ($0.32 diluted EPS).","Cash and equivalents $348.9M; cash runway extended to Q1 2027; total CSL milestones received $396M.","Kostaive (sa-mRNA COVID vaccine) approved in Japan, launch expected in 2024; ARCT-032 Phase 1b interim data expected Q2 2024.","New STARR vaccine discovery programs for Lyme disease and gonorrhea initiated; ARCT-2138 (LUNAR-FLU) Phase 1 study started."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247664,"accession_number":"0001193805-24-000264","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arcturus Therapeutics controller resigns effective March 15, 2024; assistant controller promoted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith C. Kummerfeld, SVP of Finance and Corporate Controller, resigns effective March 15, 2024 to pursue another opportunity.","Joseph Roberts, formerly Assistant Controller, promoted to Controller of the Company.","Resignation is not due to any disagreement with the Company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265116,"accession_number":"0001193805-23-001493","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q3 revenue $45.1M, net loss narrowed; cash runway extended to 2026; ARCT-154 on track for Japan approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $45.1M for Q3 2023 ($13.4M in Q3 2022); net loss $16.2M ($0.61/share) improved from $35.3M loss.","Cash, equivalents and restricted cash $369.1M; expected runway extended to end of 2026.","$35M milestone achieved from CSL Seqirus; total milestones received $365M to date.","ARCT-154 monovalent COVID vaccine on track for Japan NDA approval in December; Phase 3 bivalent trial enrollment target (850 participants) reached.","ARCT-032 Phase 1b initiated; first CF patient dosing this month; FDA Rare Pediatric Disease Designation granted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":135944000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282321,"accession_number":"0001193805-23-001328","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Arcturus extends CF Foundation deal; total funding up to ~$25M for ARCT-032 CF program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CF Foundation increases financial commitment to ~$25M to advance ARCT-032, an mRNA therapeutic for cystic fibrosis.","Arcturus to provide $15M in matching funds; royalty rates and caps modified with option to reduce via one-time payment.","Agreement extends prior program initiated in 2017; Phase 1b study in adults with CF planned imminently.","ARCT-032 is mutation-agnostic and aims to express functional CFTR protein in the lung, addressing root cause of CF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282320,"accession_number":"0001193805-23-001174","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Arcturus' JV ARCALIS awarded $115M in Japanese government grants; achieves $17.5M CSL flu milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCALIS, Arcturus' 49%-owned joint venture, receives $115M in two grants to build a cGMP mRNA factory in Minamisoma, Japan.","LUNAR-FLU program achieves $17.5M development milestone from CSL Seqirus; funds used for flu program development activities.","The factory will support cGMP production of mRNA drug substance and drug product for Arcturus' STARR mRNA vaccines.","CSL Seqirus is exclusive global licensee for mRNA vaccines against COVID-19, flu, and three other respiratory diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282319,"accession_number":"0001193805-23-001112","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arcturus Q2 net loss widens to $52.6M; ARCT-154 NDA submitted in Japan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 revenue $10.5M vs $27.1M in Q2 2022; net loss $52.6M ($1.98 EPS) vs $21.6M loss ($0.82 EPS).","Cash, equivalents and restricted cash $380.6M at June 30; cash runway extended through early 2026.","ARCT-154 Phase 3 booster met primary endpoint; Meiji Seika Pharma submitted NDA in Japan.","FDA granted Fast Track and Rare Pediatric Disease Designations for ARCT-810 (OTC deficiency).","Regulatory approval received to start ARCT-032 Phase 1b study in cystic fibrosis patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":90804000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282318,"accession_number":"0001193805-23-000984","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Arcturus announces medRxiv preprint of Phase 3 data for ARCT-154 booster vs. Comirnaty","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preprint on medRxiv reports interim Phase 3 results from Japan comparing ARCT-154 booster to Comirnaty.","Study conducted by Meiji Seika Pharma, Arcturus' collaborator, evaluating safety and immunogenicity.","Meiji has a distribution agreement with CSL Seqirus for ARCT-154 in Japan, previously announced on April 11, 2023.","The article is a preprint and has not yet been peer-reviewed; no specific results are provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301483,"accession_number":"0001193805-23-000929","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Meiji submits additional application in Japan for booster dose of Arcturus' COVID-19 vaccine ARCT-154","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Meiji Seika Pharma submitted a booster dose application for ARCT-154 in Japan based on Phase III data meeting primary endpoint.","This follows the April 28 NDA for primary immunization; ARCT-154 is a self-amplifying mRNA vaccine developed by Arcturus.","The Phase III trial (jRCT2071220080) compared ARCT-154 to COMIRNATY booster; no clinically significant safety concerns.","If approved, ARCT-154 would be a new COVID-19 vaccination option in Japan; distribution via CSL Seqirus agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301482,"accession_number":"0001193805-23-000861","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcturus Therapeutics stockholders elect eight directors, approve say-on-pay and auditor ratification at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Dr. Magda Marquet received lowest approval with 66.7% of votes for.","Non-binding advisory say-on-pay resolution approved with 11,959,501 votes for (72.4%) vs 4,562,055 against.","Ratification of Ernst & Young as auditor for FY2023 approved with 18,955,484 votes for, only 22,224 against.","Quorum established with 18,987,002 shares represented (71.5% of outstanding 26,562,951 shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301481,"accession_number":"0001193805-23-000686","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q1 net income $50.8M ($1.87 EPS) vs loss year ago; NDA filed for COVID vaccine ARCT-154 in Japan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $80.3M (up from $5.2M YoY) driven by CSL Seqirus milestones; net income $50.8M vs loss of $51.2M.","NDA for ARCT-154 (COVID-19 vaccine) submitted in Japan by Meiji Seika Pharma; potential approval later 2023.","Cash $330.1M; long-term debt eliminated; expects $90M AR collection in Q2; runway extended into early 2026.","ARCT-032 Phase 1 enrollment complete; expansion to CF patients planned Q3 2023. ARCT-810 Phase 2 interim data on track for later 2023.","Received $23.6M advance from CSL Seqirus for manufacturing and supply of ARCT-154 in April."],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":80285000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301480,"accession_number":"0001193805-23-000619","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Meiji submits NDA in Japan for ARCT-154, Arcturus' self-amplifying mRNA COVID-19 vaccine","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Meiji Seika Pharma filed NDA for primary immunization (two doses) of ARCT-154 in Japan.","NDA based on Phase III trial in Vietnam (NCT05012943) with >16,000 subjects; met primary endpoint of COVID-19 prevention.","Meiji holds exclusive Japan distribution rights from CSL Seqirus; Arcturus developed the vaccine.","ARCT-154 uses next-gen mRNA technology for strong immune response and potential lower dosing.","Meiji collaborates with ARCALIS to build mRNA manufacturing in Minami-soma, Fukushima."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301479,"accession_number":"0001193805-23-000595","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Arcturus Therapeutics enters $50M revolving credit facility with Wells Fargo","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit agreement with Wells Fargo for $50M revolving line; two-year term, renewable annually.","Borrowings bear interest at SOFR +1.00%; default rate +2.00%.","No prepayment penalty; collateral of $55M in cash pledged.","Commitment fee of 0.25% of loan amount for each renewal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301478,"accession_number":"0001193805-23-000532","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Meiji and CSL Seqirus to distribute Arcturus' COVID-19 vaccine ARCT-154 in Japan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Meiji Seika Pharma entered a distribution agreement with CSL Seqirus for Arcturus' COVID-19 vaccine candidate ARCT-154 in Japan.","Phase III trial of ARCT-154 started Dec 12, 2022, targeting 780 participants; enrollment completed with 828 in Feb 2023.","Arcturus has a Collaboration and License Agreement with CSL Seqirus since Dec 8, 2022 for global rights to self-amplifying mRNA vaccines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321283,"accession_number":"0001193805-23-000401","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q4 2022 net income $117.3M ($4.33/diluted share), revenue surge to $160.3M on CSL deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $160.3M vs $5.8M same quarter 2021; full-year revenue $206.0M vs $12.4M.","Recorded net income $117.3M ($4.33/diluted) for Q4 vs net loss $38.7M ($1.47 loss) prior year.","Received $200M upfront from CSL Seqirus in Dec 2022; $90M milestones invoiced in Mar 2023.","Cash $391.9M at Dec 31, 2022; repaid $17.1M to Singapore, eliminating $33.3M non-recourse debt.","ARCT-154 Phase 3 booster fully enrolled in Japan; ARCT-810 Phase 2 interim data expected later 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321282,"accession_number":"0001193805-23-000356","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Arcturus terminates $15M Western Alliance loan with $7.36M payoff, releases liens","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Paid ~$7.36M from cash on hand to terminate Western Alliance Bank loan agreement on March 14, 2023.","Loan originally up to $15M with floating rate prime+1.25-2.75% and maturity October 30, 2023.","Payoff includes ~$7.02M principal/interest, $300K prepayment fee tied to prior FDA IND approval, and $35K prepayment charges.","All liens under the Western Alliance Agreement have been released."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339394,"accession_number":"0001193805-22-001719","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcturus appoints former Merck Global Vaccines President John Markels to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Markels, Ph.D., appointed to Board of Directors effective December 8, 2022.","Markels most recently President of Global Vaccines at Merck; retired March 2022 after 35 years.","He will provide strategic oversight to Arcturus' vaccine franchise and manufacturing processes.","Markels also serves on the board of Sangamo Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339393,"accession_number":"0001193805-22-001712","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arcturus' COVID-19 vaccine ARCT-154 enters Phase III trial in Japan; CSL collaboration effective","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Meiji Seika Pharma initiated a Phase III trial of ARCT-154 (self-amplifying mRNA COVID-19 vaccine) in Japan with 780 participants; half receive ARCT-154 as a booster.","The trial will evaluate non-inferiority of ARCT-154 as a booster series compared to a comparator group.","CSL Seqirus announced that the previously disclosed collaboration agreement (Nov 1, 2022) with Arcturus became effective on December 8, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339392,"accession_number":"0001193805-22-001504","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q3 net loss $35.3M; CSL partnership $200M upfront, up to $4.3B milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.4M (Q3 2022) vs $2.4M YoY; net loss $35.3M ($1.33 per share).","Cash $237.7M at Sep 30, 2022, down from $370.5M at Dec 31, 2021.","CSL Seqirus collaboration: $200M upfront, up to $4.3B milestones, 40% profit share on COVID vaccines.","BARDA award of up to $63.2M for self-amplifying mRNA pandemic influenza vaccine development.","ARCT-810 OTC deficiency Phase 2 dosing starts Q4 2022; ARCT-032 CTA filing expected by year end."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":45706000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339391,"accession_number":"0001193805-22-001480","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Arcturus: Janssen ends Hep B pact, Vietnam mfg deal terminated; ARCT-154 study extended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Janssen terminated Hep B collaboration; effective in 60 days; no penalties.","Mutual termination of Vietnam COVID-19 vaccine manufacturing deals with Vinbiocare; no penalties.","New Study Support Agreement for ARCT-154 vaccine study; payments to Vinbiocare through Q1 2025 plus royalty.","Arcturus takes on financial responsibility for continuing clinical activities in Vietnam."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339390,"accession_number":"0001193805-22-001470","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Arcturus signs $200M upfront collaboration with CSL Seqirus for self-amplifying mRNA vaccines","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Arcturus receives $200M upfront; eligible for >$1.3B development and >$3B commercial milestones.","40% net profit share on COVID-19 vaccines; up to double-digit royalties on flu, pandemic, and 3 other respiratory vaccines.","Collaboration covers self-amplifying mRNA vaccines for COVID-19, influenza, pandemic preparedness, and three other respiratory diseases.","CSL Seqirus leads development and commercialization; Arcturus provides STARR technology and LUNAR delivery platform.","Transaction subject to HSR Act waiting period; J.P. Morgan advised Arcturus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356766,"accession_number":"0001193805-22-001230","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Arcturus receives $63.2M BARDA award to develop self-amplifying mRNA pandemic flu vaccine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BARDA provides up to $63.2 million over three years for pandemic influenza vaccine development using STARR self-amplifying mRNA platform.","Funding covers preclinical through Phase 1 clinical studies, including manufacturing and regulatory support.","Candidate is lower-dose, freeze-dried vaccine; Arcturus' platform has been administered to over 10,000 individuals for SARS-CoV-2.","Contract is terminable by BARDA at any time for convenience; no purchase of vaccine in scope.","Award part of U.S. government's National Strategy for Pandemic Influenza to bolster pandemic preparedness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356765,"accession_number":"0001193805-22-001152","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q2 revenue $27.1M, net loss $0.82/share; ARCT-154 booster shows durable Omicron response","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $27.1M (vs $2.0M Q2 2021); net loss $21.6M ($0.82/sh) improved from $54.6M ($2.07/sh) year ago.","ARCT-154 booster: 44-fold (BA.1) and 39-fold (BA.2) neutralizing antibody GMFR at Day 91.","ARCT-810 gets EU Orphan Medicinal Product Designation for OTC deficiency; Phase 2 study enrolling.","ARCT-154 EUA in Vietnam delayed to Q4 2022; registrational booster study expected Q4 2022.","Cash $283.5M at June 30, down from $370.5M at Dec 2021; expected to fund ops into late 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":32337000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375221,"accession_number":"0001193805-22-001014","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-06-24T23:59:59+00:00","items":["1.01","5.07","9.01"],"status":"ready","headline":"Arcturus stockholders approve 3.75M share increase to equity plan, raise director compensation caps","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amending 2019 Omnibus Equity Incentive Plan to add 3,750,000 shares of common stock.","Annual director award limit raised from $500K to $2M for new directors, lead independent director, and non-employee chair; $1M for others.","Plan amendment passed with 9,375,429 votes for, 8,044,751 against, and 286,830 abstentions (44.7% opposed).","Directors elected, say-on-pay approved, and Ernst & Young ratified as auditor for fiscal 2022.","Stockholders voted for an annual say-on-frequency vote; Board adopted every-year frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375220,"accession_number":"0001193805-22-000752","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q1 net loss $51.2M ($1.94/share); ARCT-154 booster shows 54-fold Omicron BA.1 response","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2022 revenue $5.2M (up from $2.1M YoY); operating expenses $55.6M; net loss $51.2M.","Cash $319.7M at March 31, 2022; expected to fund operations into late 2023.","ARCT-154 booster data: 54-fold and 46-fold GMFR against Omicron BA.1 and BA.2 at Day 29.","Primary vaccine efficacy 95.3% against severe COVID-19; 55% overall; 98.4% seroconversion.","ARCT-810 Phase 2 OTC deficiency trial to start Q2 2022; ARCT-032 cystic fibrosis CTA filing on track for Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":5244000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375219,"accession_number":"0001193805-22-000672","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Arcturus ARCT-154 Phase 3 shows 55% efficacy vs COVID-19, 95% vs severe disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two 5-mcg doses of ARCT-154 provided 55% efficacy (95% CI 46.9-61.9) against symptomatic COVID-19.","Vaccine demonstrated 95.3% efficacy (95% CI 80.4-98.9) against severe COVID-19 including deaths.","No cases of myocarditis or pericarditis reported; unsolicited adverse events comparable to placebo.","Data submitted to Vietnam Ministry of Health for EUA; ARCT-154 advancing to pivotal booster trial in major markets.","Also amended loan with Western Alliance Bank to extend interest-only payments to Aug 1, 2022, and terminated Israeli supply deal for first-gen vaccine (no penalty)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-20T23:59:59+00:00|375219"}